2Maruyama A,Macdonald S,Borycki E,et al.Hypertension,chronic obstructive pulmonary disease,diabetes and depression among older methadone maintenance patients in British Columbia[J].Drug&Alcohol Review,2013,32(4):412-418.
3Ehrlich SF,Quesenberry CP Jr,Van Den Eeden SK,et al.Patients diagnosed with diabetes are at increased risk for asthma,chronic obstructive pulmonary disease,pulmonary fibrosis,and pulmonnia but not lung caner[J].Diabetes Care,2010,533-558.
4Mcallister PE,Bebak J.Behavioral Intervention Improves Sleep in Alzheimers Patients[J].Journal of Health Organisation&Management,2015,29(6):201-207.
6Koutsokera A,Kostikas K,Nicod L P,et al.Pulmonary biomarkers in COPD exacerbations:a systematic review.[J].Respiratory Research,2013,14(1):1-12.
7Liu HC,Lu MC,et al.Differences in IL-8in serum and exhaled breath condensate from patients with exacerbated COPD or asthma attack[J].J Formos Med Assoc,2014,113(12):908-914.
8Liu H C,Lu MC,et al.Differences in IL-8in serum and exhaled breath condensate from patients with exacerbated COPD or asthma attack[J].J Formos Med Assoc,2014,113(12):908-914.
10Pikhartova J,Blane D,Netuveli G.The role of childhood social position in adult type 2diabetes:evidence from the English Longitudinal Study of Ageing[J].Bmc Public Health,2014,77(2014):126-130.
二级参考文献44
1Schmidt MI,Duncan BB,Sharrett AR,et al.Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Riskin Communities study):a cohort study.Lancet,1999,353:1649-1652.
2Pradhan AD,Manson JE,Rifai N,et al.C-reactive protein,interleukin 6,and risk of developing type 2 diabetes mellitus.JAMA,2001,286:327-334.
3Freeman DJ,Nor'ie J,Caslake MJ,et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.Diabetes,2002,51:1596-1600.
4Festa A,D'Agostino R Jr,Tracy RP,et al.Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:the insulin resistance atherosclerosis study.Diabetes,2002,51:1131-1137.
5Brooks-Worrell BM,Reichow JL,Goel A,et al.Identification of autoantibody-negative autoimmune type 2 diabetic patients.Diabetes Care,2011,34:168-173.
6Tabák AG,Kivimaki M,Brunner EJ,et al.Changes in Creactive protein levels before type 2 diabetes and cardiovascular death:theWhitehall Ⅱ study.Eur J Endocrinol,2010,163:89-95.
7Schroder K,Zhou R,Tschopp J.The NLRP3 inflammasome:a sensor for metabolic danger?.Science,2010,327:296-300.
8Carstensen M,Herder C,Kivimaki M,et al.Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years beforediagnosis of type 2 diabetes:Whitehall Ⅱ prospective cohort study.Diabetes,2010,59:1222-1227.
9Luotola K,Pietil(a) A,Zeller T,et al.Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levelsand the development of type 2 diabetes.J Intern Med,2011,269:322-332.
10TabákAG,Carstensen M,Witte DR,et al.Adiponectin trajectories before type 2 diabetes diagnosis:Whitehall Ⅱ study.Diabetes Care,2012,35:2540-2547.
